What changed between these versions
A substantive expansion and clarification. V2 introduces a new definition for "biological data" and explicitly adds biotechnology as a key area of focus for the network's purposes and node designation. Crucially, v2 adds a new section authorizing $30 million annually for fiscal years 2026 through 2030 to fund the network's nodes, providing a clear financial framework.
Overview
There are a handful of substantive changes across several sections, including new definitions, expanded purposes, and modified designation criteria. · V2 expands the network's policy direction by explicitly emphasizing biotechnology and provides concrete financial support for its implementation, clarifying the operational framework.
The most significant change in v2 is the addition of a new Section 7, which authorizes $30,000,000 annually for fiscal years 2026 through 2030 to fund the National Programmable Cloud Laboratories Network, providing a clear financial framework. Additionally, v2 expands the network's focus to explicitly include biotechnology, adding a definition for "biological data," incorporating biotechnology into the network's purposes, and creating a preference for nodes capable of supporting cloud-enabled biotechnology research. Most other core provisions regarding the network's establishment, application, and responsibilities remain largely consistent, with minor clarifications.
Major additions
This new paragraph defines "biological data" as information, including associated descriptors, derived from the structure, function, or process of a biological system that is measured, collected, or aggregated for analysis.
This definition formally incorporates biological data into the bill's scope, clarifying its relevance for programmable cloud laboratories and setting the stage for subsequent provisions that specifically mention biotechnology and biological data. It ensures that research involving biological systems is explicitly covered.
This new purpose states that one of the Network's objectives is "to provide funding for nodes."
This explicitly establishes funding as a core purpose of the network, aligning with the new grant award provisions and the overall funding section. It signals the intent to financially support the designated laboratories.
This new subparagraph mandates that the Director shall award a grant to each designated node, with each grant not exceeding $5,000,000 per fiscal year for a period of not more than 5 years.
This provision establishes a concrete funding mechanism and amount for the operational support of each node, providing financial certainty and a clear incentive for eligible entities to apply for designation. It directly impacts the financial viability and planning for potential nodes.
This new paragraph requires the Director, to the extent practicable, to ensure that at least one designated node demonstrates the capability to support cloud-enabled biotechnology research, including automated experimentation or quality control workflows.
This provision creates a specific requirement for the network to include biotechnology research capabilities, ensuring that this critical scientific area is represented. It will influence the selection process and the composition of the network, favoring applicants with strong biotechnology infrastructure.
This new section, titled "FUNDING," authorizes the Director of the National Science Foundation to allocate $30,000,000 for each of the fiscal years 2026 through 2030 to carry out the Act, subject to the availability of appropriations.
This is a major addition that provides a specific funding authorization for the entire Act, ensuring that the National Programmable Cloud Laboratories Network has a dedicated budget for its establishment and operation over a five-year period. This significantly enhances the feasibility and long-term planning of the network.
Modifications
This is a structural change to accommodate a new definition, but it does not alter the substance or meaning of the renumbered definitions themselves. It ensures logical sequencing after the insertion of "biological data."
Before
Definitions for "Director," "Institution of higher education," "Network," "Node," "Non-designated laboratory," and "Programmable cloud laboratory" were numbered (2) through (7) respectively.
After
Due to the insertion of a new definition for "Biological data" as (2), the subsequent definitions for "Director," "Institution of higher education," "Network," "Node," "Non-designated laboratory," and "Programmable cloud laboratory" are renumbered to (3) through (8) respectively.
This explicitly broadens the strategic focus of the Network to encompass biotechnology, signaling its importance for national leadership and competitiveness. It directs the network's efforts to include advancements in this field.
Before
Stated a purpose to maintain US leadership in advanced experimentation, laboratory automation, and artificial intelligence for scientific research, advanced manufacturing, long-term economic competitiveness, and national security.
After
Modifies the purpose to maintain US leadership in advanced experimentation, biotechnology, laboratory automation, and artificial intelligence for scientific research, advanced manufacturing, long-term economic competitiveness, and national security.
This explicitly includes biotechnology in the effort to build a domestic industrial base for scientific automation tools, encouraging the development and manufacturing of biotechnology-related equipment and systems within the United States.
Before
Stated a purpose to advance the development of a domestic industrial base for scientific automation tools, artificial intelligence systems for experimentation, and robotics platforms for use in laboratory settings.
After
Modifies the purpose to advance the development of a domestic industrial base for scientific automation tools, biotechnology, artificial intelligence systems for experimentation, and robotics platforms for use in laboratory settings.
This change reflects the new grant award provisions introduced within this subsection, making the heading more descriptive of its content.
Before
The heading for subsection (b) was "Establishment."
After
The heading for subsection (b) is "Establishment; Awards."
This structural change accommodates the insertion of the new `(B) Awards` subparagraph, allowing for the explicit detailing of grant awards for nodes within the establishment section.
Before
The subsection began with `(1) In general.--Not later than 1 year after the date of enactment of this Act, the Director... shall designate and oversee...`
After
The original text of `(b)(1)` is now contained within `(b)(1)(A) Establishment.--Not later than 1 year after the date of enactment of this Act, the Director... shall designate and oversee...`
This change refines the language describing the evaluation process without altering the core principles of competitiveness, merit, and transparency. The criteria for evaluation remain unchanged.
Before
The Director was required to ensure the selection process "shall be competitive, merit-reviewed, and transparent, evaluating--".
After
The Director is required to ensure the selection process "is competitive, merit-based, and transparent, through the evaluation of, with respect to each entity--".
This structural change accommodates the insertion of the new `(2)` subparagraph, which introduces an additional preference criterion related to biotechnology capabilities. The original preference remains intact.
Before
Stated that "In designating nodes, the Director shall provide preference for applications demonstrating meaningful third-party cost share and pre-existing infrastructure."
After
States that "In designating nodes, the Director shall-- (1) give preference to applicants demonstrating meaningful third-party cost share and pre-existing infrastructure;".
Nodes are now explicitly required to support the development of a domestic industrial base for scientific automation tools, including biotechnology, as a primary responsibility, rather than solely focusing on furthering programmable cloud laboratory research in various disciplines. This emphasizes industrial development.
Before
Required each node to "support the purposes described in subsection (a)(9);". In v1, (a)(9) referred to furthering programmable cloud laboratory research in areas like materials science, biotechnology, and chemistry.
After
Still requires each node to "support the purposes described in subsection (a)(9);". However, due to the insertion of a new (a)(8), the new (a)(9) in v2 refers to advancing the development of a domestic industrial base for scientific automation tools, biotechnology, artificial intelligence systems, and robotics platforms. The original (a)(9) is now (a)(10).
This ensures that biological data is explicitly included in the secure data-sharing protocols, reinforcing the network's commitment to biotechnology research and data management.
Before
Required nodes to support secure sharing of experimental data, models, and results across institutions of higher education.
After
Requires nodes to support secure sharing of experimental data, including biological data, models, and results across institutions of higher education.
This clarifies that the interoperability standards and data-sharing protocols developed by NIST must specifically accommodate biological data, further integrating biotechnology into the network's operational framework.
Before
Required the Director of NIST to establish protocols for secure, seamless, and standardized data-sharing among all members of the Network.
After
Requires the Director of NIST to establish protocols for secure, seamless, and standardized data-sharing among all members of the Network, including sharing of biological data, aligned with node-level cybersecurity and research security protocols.
This minor addition clarifies that the intellectual property considerations are specifically related to participation in the National Programmable Cloud Laboratories Network, making the scope more precise.
Before
Identified legal, contractual, or intellectual property considerations that may affect participation.
After
Identified legal, contractual, or intellectual property considerations that may affect participation in the Network.
This is a structural change to accommodate the insertion of the new Section 7 (Funding). The content and effect of the sunset provision remain unchanged.
Before
The sunset provision was in Section 7.
After
The sunset provision is renumbered to Section 8.
Scope
Meaningful expansion or narrowing — Changes are concentrated in the definitions (Section 2), purposes (Section 3(a)), establishment (Section 3(b)), and designation criteria (Section 3(f)), with a significant new section for funding (Section 7). — V2 represents a meaningful expansion in policy direction by explicitly integrating biotechnology as a core focus area and by establishing a concrete funding authorization for the network, which was absent in v1. — The new definition of "biological data" and the explicit mention of biotechnology interact with and clarify the scope of data sharing, research focus, and node responsibilities across multiple sections (e.g., Section 3(a), 3(f), 3(g), 4). The new funding section provides the financial backbone for the entire Act.
Impact analysis
Researchers and institutions engaged in biotechnology research
Gain
V2 explicitly recognizes and emphasizes biotechnology as a key area for the network, defining "biological data," adding biotechnology to the network's purposes, and requiring at least one node to support cloud-enabled biotechnology research. Data sharing protocols are also explicitly extended to biological data.
Eligible entities applying for node designation
Gain
V2 provides a clear funding structure, specifying grants of up to $5,000,000 per fiscal year for 5 years. It also introduces a specific preference for applicants demonstrating cloud-enabled biotechnology research capabilities.
The National Science Foundation (NSF) Director
Gain
V2 adds "to provide funding for nodes" as an explicit purpose of the network and provides a specific funding authorization of $30,000,000 annually for FY2026-2030 to carry out the Act.
Domestic industrial base for scientific automation tools
Gain
V2 explicitly adds "biotechnology" to the list of areas for which the network aims to advance the development of a domestic industrial base. Additionally, nodes are now specifically required to support this expanded purpose.